Dr. Fader on Adding Trastuzumab to Chemo in HER2+ Uterine Serous Carcinoma
April 9th 2020
Amanda Nickles Fader, MD, discusses findings from a randomized phase II trial examining the efficacy of adding trastuzumab to carboplatin/paclitaxel in patients with advanced or recurrent uterine serous carcinomas that overexpress HER2/neu.